Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ziltivekimab bioavailability study in healthy volunteers
NCT05721989Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Feb 2023
- Primary completion
- Jan 2024
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, randomised, open-label trial of ziltivekimab (3 arms), sponsored by Novo Nordisk. Primary endpoint: Area under the ziltivekimab serum concentration-time curve from 0 hours and extrapolated to infinity after a single dose at 183 days. Started Feb 2023; status: completed.
02
Drugs
ziltivekimab
Beyond the preview
Go deeper on NCT05721989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05721989.